{
  "ticker": "NEO",
  "company_name": "NeoGenomics, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT05077709",
      "title": "IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Lung Cancer Non Small Cell, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma Bladder",
      "start_date": "2022-02-14",
      "completion_date": "2024-11-30",
      "enrollment": 0,
      "sponsor": "IO Biotech"
    },
    {
      "nct_id": "NCT05414032",
      "title": "Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)",
      "start_date": "2023-07-12",
      "completion_date": "2026-07",
      "enrollment": 0,
      "sponsor": "University Health Network, Toronto"
    }
  ],
  "summary": {
    "total_trials": 2,
    "by_phase": {
      "PHASE2": 2
    },
    "by_status": {
      "ACTIVE_NOT_RECRUITING": 1,
      "RECRUITING": 1
    },
    "active_trials": 2,
    "completed_trials": 0,
    "conditions": [
      "Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)",
      "Lung Cancer Non Small Cell, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma Bladder"
    ],
    "lead_stage": "phase_2"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:36:11.908008",
    "search_query": "NeoGenomics, Inc.",
    "url": "https://clinicaltrials.gov/search?term=NeoGenomics,+Inc."
  }
}